TAVI at 10 Years: First Study to Assess TAVI Long Term Durability

Original Title: First look at long-term durability of transcatheter heart valves: Assessment of valve function up to 10 years after implantation.
Presenter: Danny Dvir.

 

Transcatheter aortic valve implantation (TAVI) is being used in increasingly younger patients at low surgical risk, which is why longer survival is expected. The durability of transcatheter aortic prostheses has been assessed only at short or medium term.

 

The goal of this study was to assess long term valve deterioration risk. The study included patients implanted ≥5 years prior to the study (range 5 to 14 years) in 2 centers in Canada, all receiving the balloon expandable valves Cribier Edwards, Edwards SAPIENS, SAPIENS XT.

 
Valve degeneration was defined as aortic regurgitation, at least moderate, and/or a post procedural >20mmHg mean gradient apparent after the first 30 days, not associated to infectious endocarditis.

 
In all, the study assessed 378 with a mean survival rate of 51 months, and 2 patients to survive 10 years after procedure.
35 patients matched the valve degeneration criteria (23 regurgitation and 12 stenosis). Degeneration mean time was 61 months.

 

 

Conclusion
This is the first analysis at such long term after TAVI; it showed significant valve degeneration between years 5 and 7 (at 8 years almost 50% present valve degeneration) and this is often associated to kidney failure.

 

 

tavi-a-10-años

More articles by this author

OPINON: OCT vs. IVUS Guided PCI

Original Title: Optical frequency domain imaging vs. IVUS in PCI: the OPINION trial – one-year primary endpoint results. Presenter: T. Kubo.   Optical coherence tomography (OCT) is...

LEADERS FREE ACS: Biolimus coated stent vs. bare metal stent in ACS with high bleeding risk

Original Title: Biolimus A9 drug-coated stent vs. bare metal stent in patients presenting with ACS. A pre-specified LEADERS FREE ACS sub-study. Presenter: C.K. Naber.   In ACS...

FANTOM II: New sirolimus eluting bioresorbable scaffold

Original Title: Fantom sirolimus-eluting BRS – FANTOM II Trial. Presenter: Alexandre Abizaid   This new sirolimus eluting bioresorbable scaffold is the only one which can be directly...

EWOLUTION: Outcomes of left atrial appendage closure in the real world

Original Title: EWOLUTION: 3-months outcome of Left Atrial Appendage Closure with the WATCHMAN device in Europe. Presenter: Martin Bergmann.   This study presented the experience of left...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....